Genomma Lab Internacional, S.A.B. de C.V.
GNMLF
$1.43
$0.169913.48%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 976.04M | 953.16M | 929.55M | 938.43M | 895.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 976.04M | 953.16M | 929.55M | 938.43M | 895.82M |
| Cost of Revenue | 360.45M | 359.74M | 360.29M | 370.20M | 355.61M |
| Gross Profit | 615.58M | 593.42M | 569.25M | 568.23M | 540.21M |
| SG&A Expenses | 411.80M | 399.97M | 385.77M | 385.06M | 368.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 4.49M | 1.98M | -512.40K | -148.80K | -2.36M |
| Total Operating Expenses | 776.74M | 761.69M | 745.55M | 755.12M | 721.97M |
| Operating Income | 199.29M | 191.47M | 184.00M | 183.31M | 173.86M |
| Income Before Tax | 117.58M | 101.17M | 97.01M | 117.90M | 116.11M |
| Income Tax Expenses | 40.75M | 37.40M | 36.00M | 40.90M | 41.11M |
| Earnings from Continuing Operations | 76.83 | 63.77 | 61.01 | 77.00 | 75.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 76.83M | 63.77M | 61.01M | 77.00M | 75.01M |
| EBIT | 199.29M | 191.47M | 184.00M | 183.31M | 173.86M |
| EBITDA | 213.73M | 205.89M | 196.79M | 196.84M | 186.71M |
| EPS Basic | 0.08 | 0.07 | 0.06 | 0.08 | 0.08 |
| Normalized Basic EPS | 0.08 | 0.07 | 0.06 | 0.08 | 0.07 |
| EPS Diluted | 0.08 | 0.07 | 0.06 | 0.08 | 0.08 |
| Normalized Diluted EPS | 0.08 | 0.07 | 0.06 | 0.08 | 0.07 |
| Average Basic Shares Outstanding | 3.79B | 3.82B | 3.83B | 3.88B | 3.93B |
| Average Diluted Shares Outstanding | 3.79B | 3.82B | 3.83B | 3.88B | 3.93B |
| Dividend Per Share | 0.03 | 0.05 | 0.04 | 0.05 | 0.04 |
| Payout Ratio | 59.52% | 70.00% | 54.64% | 54.44% | 40.75% |
